Literature DB >> 19953221

Are macrolides now obligatory in severe community-acquired pneumonia?

Grant W Waterer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19953221     DOI： 10.1007/s00134-009-1734-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  15 in total

1.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

Authors:  José A Martínez; Juan P Horcajada; Manuel Almela; Francesc Marco; Alex Soriano; Elisa García; Maria Angeles Marco; Antoni Torres; Josep Mensa
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

2.  Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

Authors:  M A Mufson; R J Stanek
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

3.  Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.

Authors:  Evangelos J Giamarellos-Bourboulis; Fotini Baziaka; Anastasia Antonopoulou; Pantelis Koutoukas; Vassilios Kousoulas; Lambros Sabracos; Charalambos Panagou; Despina Perrea; Helen Giamarellou
Journal:  Int J Antimicrob Agents       Date:  2005-02       Impact factor: 5.283

4.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.

Authors:  G W Waterer; G W Somes; R G Wunderink
Journal:  Arch Intern Med       Date:  2001 Aug 13-27

5.  Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones.

Authors:  Mark L Metersky; Allen Ma; Peter M Houck; Dale W Bratzler
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

6.  Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs.

Authors:  Antonella Zambon; Hernan Polo Friz; Paolo Contiero; Giovanni Corrao
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.

Authors:  I Martin-Loeches; T Lisboa; A Rodriguez; C Putensen; D Annane; J Garnacho-Montero; M I Restrepo; J Rello
Journal:  Intensive Care Med       Date:  2009-12-02       Impact factor: 17.440

8.  Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis.

Authors:  Oscar Cirioni; Roberto Ghiselli; Carmela Silvestri; Wojciech Kamysz; Fiorenza Orlando; Alessandra Riva; Elzbieta Kamysz; Sefora Castelletti; Marco Rocchi; Vittorio Saba; Giorgio Scalise; Andrea Giacometti
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

9.  Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro.

Authors:  R Anderson; H C Steel; R Cockeran; A von Gottberg; L de Gouveia; K P Klugman; T J Mitchell; C Feldman
Journal:  J Antimicrob Chemother       Date:  2007-09-10       Impact factor: 5.790

10.  The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.

Authors:  Eric M Mortensen; Marcos I Restrepo; Antonio Anzueto; Jacqueline Pugh
Journal:  Crit Care       Date:  2005-12-06       Impact factor: 9.097
View more
  1 in total

1.  Questions remain regarding mandatory use of macrolides in community-acquired pneumonia.

Authors:  Benjamin P Westley; Philip A Chan
Journal:  Intensive Care Med       Date:  2010-07-15       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.